In one of the largest population-based studies, Rinaldi et al. found that the activity level of GPx-3 was similarly lower in MCI (n = 25) and AD (n = 63) patients as compared with controls (n = 53) [54]. This evidence concerns the gene GPX3 and Alzheimer disease.